{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:16:28Z","timestamp":1788264988375,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.semarthrit.2021.11.003","type":"journal-article","created":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T17:18:02Z","timestamp":1636305482000},"page":"151926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Symptom experience of limited cutaneous systemic sclerosis from the Patients\u2019 perspective: A qualitative study\u2730,\u2730\u2730,\u2605,\u2605\u2605"],"prefix":"10.1016","volume":"52","author":[{"given":"Alain","family":"Lescoat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen T","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Vann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Del","family":"Galdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya H","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2021.11.003_bib0001","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/art.40799","article-title":"Ulnar artery occlusion and severity markers of vasculopathy in systemic sclerosis: a multicenter cross-sectional study","volume":"71","author":"Lescoat","year":"2019","journal-title":"Arthrit Rheumatol (Hoboken, N.J.)"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0002","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0003","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0004","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0005","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2665-9913(19)30038-4","article-title":"The nosology of systemic sclerosis: how lessons from the past offer new challenges in reframing an idiopathic rheumatological disorder","volume":"1","author":"Lescoat","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102452","article-title":"Outcomes of limited cutaneous systemic sclerosis patients: results on more than 12,000 patients from the EUSTAR database","volume":"19","author":"Frantz","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0007","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3899\/jrheum.121390","article-title":"Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis","volume":"40","author":"Hoffmann-Vold","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0008","article-title":"Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes","author":"Lescoat","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0009","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American college of rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthrit Rheumatol (Hoboken, N.J.)"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0010","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American college of rheumatology composite response index in systemic sclerosis","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0011","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30010-2","article-title":"The future of treatment in systemic sclerosis: can we design better trials?","volume":"2","author":"Pope","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0012","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a Phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthrit Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0013","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.11.003_bib0014","first-page":"S486","article-title":"The future of measuring patient-reported outcomes in rheumatology: patient-Reported Outcomes Measurement Information System (PROMIS)","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0015","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/2397198319886496","article-title":"Patient-reported outcome instruments in clinical trials of systemic sclerosis","volume":"5","author":"Pauling","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0016","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5301\/jsrd.5000216","article-title":"Limited cutaneous systemic sclerosis: the unfairly neglected subset","volume":"1","author":"Allanore","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0017","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-021-02548-1","article-title":"Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort","volume":"23","author":"Jaafar","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0018","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/ard.2007.078923","article-title":"Development of a provisional core set of response measures for clinical trials of systemic sclerosis","volume":"67","author":"Khanna","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0019","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1188\/03.ONF.601-606","article-title":"Symptoms experience: a concept analysis","volume":"30","author":"Armstrong","year":"2003","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044765","article-title":"Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol","volume":"11","author":"Lescoat","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.apmr.2003.08.109","volume":"85","author":"White","year":"2004","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0022","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American college of Rheumatology\/European league against rheumatism collaborative initiative: ACR\/EULAR classification criteria for SSc","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheumatism"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0023","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/rheumatology\/key026","article-title":"The patient experience of Raynaud's phenomenon in systemic sclerosis","volume":"58","author":"Pauling","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0024","series-title":"Focus Groups: A Practical Guide for Applied Research","author":"Krueger","year":"2000"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0025","article-title":"Methodological aspects of focus groups in health research: results of qualitative interviews with focus group moderators","volume":"3","author":"Tausch","year":"2016","journal-title":"Glob Qual Nurs Res"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0026","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1525822X05279903","article-title":"How many interviews are enough?: an experiment with data saturation and variability","volume":"18","author":"Guest","year":"2006","journal-title":"Field methods"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0027","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3899\/jrheum.160602","article-title":"Qualitative methods in systemic sclerosis research","volume":"43","author":"Johnson","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0028","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2648.2006.04043.x","article-title":"Best practice\u2019 in focus group research: making sense of different views","volume":"56","author":"Freeman","year":"2006","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0029","unstructured":"Lupus Patient-Focused Drug Development Meeting | Lupus Foundation of America\u00a0 [Internet].\u00a0 [cited 2021 Jul 6];Available from: http:\/\/www.lupus.org\/PFDD-meeting"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0030","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/acr.24127","article-title":"Multicenter qualitative study exploring the patient experience of digital ulcers in systemic sclerosis","volume":"72","author":"Hughes","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/1609406917712131","article-title":"Rapid and rigorous qualitative data analysis: the \u201cRADaR\u201d technique for applied research","volume":"16","author":"Watkins","year":"2017","journal-title":"Int J Qual Methods"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0032","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0033","unstructured":"Patton M. In: Qualitative Research and Evaluation Methods. CA: SAGE; 200AD."},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0034","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/acr.24027","article-title":"Scope and consistency of outcomes reported in trials of patients with systemic sclerosis","volume":"72","author":"Sumpton","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0035","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/acr.23475","article-title":"Multinational qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis","volume":"70","author":"Pauling","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0036","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3899\/jrheum.151309","article-title":"Patients\u2019 perspectives and experiences living with systemic sclerosis: a systematic review and thematic synthesis of qualitative studies","volume":"43","author":"Nakayama","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0037","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/ard.2010.148767","article-title":"Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries","volume":"70","author":"Stamm","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0038","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective european scleroderma trials and research cohort of patients with systemic sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0039","article-title":"Fatigue and its association with social participation, functioning and quality of life in systemic sclerosis","author":"Murphy","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0040","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s10067-021-05598-7","article-title":"How do patients define Raynaud's phenomenon? Differences between primary and secondary disease","volume":"40","author":"Murphy","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0041","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/jama.2016.5258","article-title":"Effect of Macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials","volume":"315","author":"Khanna","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0042","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0043","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/BOR.0000000000000795","article-title":"Treatment for systemic sclerosis-associated interstitial lung disease","volume":"33","author":"Roofeh","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0044","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1093\/rheumatology\/keaa742","article-title":"Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis","volume":"60","author":"Dumitru","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2021.11.003_bib0046","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/BOR.0000000000000747","article-title":"Novel classifications for systemic sclerosis: challenging historical subsets to unlock new doors","volume":"32","author":"Sobanski","year":"2020","journal-title":"Curr Opin Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:08:06Z","timestamp":1758733686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017221001992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":46,"alternative-id":["S0049017221001992"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptom experience of limited cutaneous systemic sclerosis from the Patients\u2019 perspective: A qualitative study\u2730,\u2730\u2730,\u2605,\u2605\u2605","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151926"}}